Characterization of the novel HLA-DPB1*1098:01N allele by sequencing-based typing.


Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
08 2020
Historique:
received: 25 05 2020
accepted: 25 05 2020
pubmed: 31 5 2020
medline: 22 6 2021
entrez: 31 5 2020
Statut: ppublish

Résumé

HLA-DPB1*1098:01N differs from HLA-DPB1*03:01:01:01 by one nucleotide substitution in codon 128 in exon 3.

Identifiants

pubmed: 32473081
doi: 10.1111/tan.13953
doi:

Substances chimiques

HLA-DP beta-Chains 0
HLA-DPB1 antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-251

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Cargou M, Ralazamahaleo M, Blouin L, et al. Evaluation of the AllType kit for HLA typing using the Ion Torrent S5 XL platform. HLA. 2019;95:30-39. https://doi.org/10.1111/tan.13708.
Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SGE. IPD-IMGT/HLA Database. Nucleic Acids Res. 2020;48(D1):D948-D955. https://doi.org/10.1093/nar/gkz950.
Bouthemy C, Ralazamahaleo M, Jollet I, Filloux M, Visentin J, Guidicelli G. Improvement in HLA-typing by new sequence-specific oligonucleotides kits for HLA-A, -B and -DRB1 loci. HLA. 2018;92(5):279-287. https://doi.org/10.1111/tan.13382.
Visentin J, Bachelet T, Borg C, et al. Reassessment of T lymphocytes crossmatches results prediction with Luminex Class I single antigen flow beads assay. Transplantation. 2017;101(3):624-630. https://doi.org/10.1097/TP.0000000000001239.
Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291-455. https://doi.org/10.1111/j.1399-0039.2010.01466.x.

Auteurs

Marine Cargou (M)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.
Université de Bordeaux, UMR CNRS 5164 Immunoconcept, Bordeaux, France.

Vincent Elsermans (V)

CHRU de Lille, Institut d'Immunologie-HLA, Lille, France.

Isabelle Top (I)

CHRU de Lille, Institut d'Immunologie-HLA, Lille, France.

Gwendaline Guidicelli (G)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.

Jonathan Visentin (J)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.
Université de Bordeaux, UMR CNRS 5164 Immunoconcept, Bordeaux, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH